Global Pregabalin Market to Grow by $153.03 Million During 2022-2026 – ResearchAndMarkets.com

Global Pregabalin Market to Grow by $153.03 Million During 2022-2026 – ResearchAndMarkets.com




Global Pregabalin Market to Grow by $153.03 Million During 2022-2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Pregabalin Market 2022-2026” report has been added to ResearchAndMarkets.com’s offering.

The pregabalin market is poised to grow by $153.03 mn during 2022-2026, accelerating at a CAGR of 3.74% during the forecast period. The report on the pregabalin market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the presence of a large patient pool related to neuropathic pain, an increasing geriatric population, and rising applications of pregabalin in various diseases.

The pregabalin market analysis includes the application segment and geographic landscape.

The pregabalin market is segmented as below: By Application

  • Neuropathic pain
  • Epilepsy
  • Anxiety disorders
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the growing focus on emerging economies as one of the prime reasons driving the pregabalin market growth during the next few years. Also, increasing incidence of diabetes and HIV and rising healthcare expenditure will lead to sizable demand in the market.

The report on the pregabalin market covers the following areas:

  • Pregabalin market sizing
  • Pregabalin market forecast
  • Pregabalin market industry analysis

Key Topics Covered:

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Application

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

Companies Mentioned

  • Biomax Biotechnics Pvt. Ltd.
  • Camber Pharmaceuticals Inc.
  • Cipla Ltd.
  • Dr. Kumars Pharmaceuticals
  • Genesis Biotec Inc.
  • H. L. Healthcare Pvt. Ltd.
  • Lupin Ltd
  • Medley Pharmaceuticals Ltd.
  • MK Medicine
  • MSN Laboratories
  • Neuracle Lifesciences Pvt. Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Phoenix Biologicals Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Swastik Life Sciences
  • Torrent Pharmaceuticals Ltd.
  • Vibcare Pharma Pvt. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/1ze7yx

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900